Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2002 Dec;11(6):345–349. doi: 10.1080/0962935021000051539

Tumour necrosis factor-alpha, interleukin-2 soluble receptor and different inflammatory parameters in patients with rheumatoid arthritis.

Tânia Silvia Fröde 1, Patrícia Tenconi 1, Marilei Reynaud Debiasi 1, Yara Santos Medeiros 1
PMCID: PMC1781685  PMID: 12581498

Abstract

BACKGROUND AND AIMS: Although the participation of cytokines in the pathogenesis of rheumatoid arthritis (RA) seems to be unequivocal, their relationship with current serum markers of this disease is not clear. The present study analyses whether there is any correlation between the levels of tumour necrosis factor-alpha (TNF-alpha), interleukin-2 soluble receptor (sIL-2R) and the concentrations of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and beta(2)-microglobulin in a group of 21 patients with RA, all rheumatoid factor positive. METHODS: The levels of TNF-alpha and sIL-2R were analysed in association with other parameters of inflammation (ESR, CRP and beta(2)-microglobulin). RESULTS: In comparison with the control group, RA patients presented high median levels of both cytokines, TNF-alpha (6.4 pg/ml) and sIL-2R (56 pmol/L), as well as of ESR (34 mm/h), CRP (0.9 mg/dl) and beta(2)-microglobulin (1.6 mg/dl) (p < 0.01). However, only ESR levels in the RA group significantly differ from the control group (p < 0.01). No correlation was found between the inflammatory parameters. CONCLUSIONS: These results suggested that TNF-alpha and slL-2R levels are up-regulated in RA patients but did not significantly differ from the control group. Due to the chronic course of this disease, other inflammatory markers must be identified in order to provide early therapeutic strategies to these patients.

Full Text

The Full Text of this article is available as a PDF (152.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Butler D. M., Maini R. N., Feldmann M., Brennan F. M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw. 1995 Jul-Dec;6(4):225–230. [PubMed] [Google Scholar]
  2. Carteron N. L. Cytokines in rheumatoid arthritis: trials and tribulations. Mol Med Today. 2000 Aug;6(8):315–323. doi: 10.1016/s1357-4310(00)01757-3. [DOI] [PubMed] [Google Scholar]
  3. Corrigall V. M., Arastu M., Khan S., Shah C., Fife M., Smeets T., Tak P. P., Panayi G. S. Functional IL-2 receptor beta (CD122) and gamma (CD132) chains are expressed by fibroblast-like synoviocytes: activation by IL-2 stimulates monocyte chemoattractant protein-1 production. J Immunol. 2001 Mar 15;166(6):4141–4147. doi: 10.4049/jimmunol.166.6.4141. [DOI] [PubMed] [Google Scholar]
  4. Koch A. E., Kunkel S. L., Strieter R. M. Cytokines in rheumatoid arthritis. J Investig Med. 1995 Feb;43(1):28–38. [PubMed] [Google Scholar]
  5. Koenig W. C-Reactive protein and cardiovascular risk: has the time come for screening the general population? Clin Chem. 2001 Jan;47(1):9–10. [PubMed] [Google Scholar]
  6. Maini R. N. The role of cytokines in rheumatoid arthritis. The Croonian Lecture 1995. J R Coll Physicians Lond. 1996 Jul-Aug;30(4):344–351. [PMC free article] [PubMed] [Google Scholar]
  7. McDermott M. F. TNF and TNFR biology in health and disease. Cell Mol Biol (Noisy-le-grand) 2001 Jun;47(4):619–635. [PubMed] [Google Scholar]
  8. Mugnier B., Bouvenot G. Les anticorps monoclonaux anti-TNF-alpha dans le traitement de la polyarthrite rhumatoïde. Rev Med Interne. 2000 Oct;21(10):854–862. doi: 10.1016/s0248-8663(00)00236-8. [DOI] [PubMed] [Google Scholar]
  9. Møller H. J. Connective tissue markers of rheumatoid arthritis. Scand J Clin Lab Invest. 1998 Jul;58(4):269–278. doi: 10.1080/00365519850186445. [DOI] [PubMed] [Google Scholar]
  10. Pincus T. Rheumatoid arthritis: a medical emergency? Scand J Rheumatol Suppl. 1994;100:21–30. doi: 10.3109/03009749409095198. [DOI] [PubMed] [Google Scholar]
  11. Richardson C., Emery P. Laboratory markers of disease activity. J Rheumatol Suppl. 1996 Mar;44:23–30. [PubMed] [Google Scholar]
  12. Rifai N., Ridker P. M. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin Chem. 2001 Mar;47(3):403–411. [PubMed] [Google Scholar]
  13. Spadaro A., Taccari E., Riccieri V., Sensi F., Sili Scavalli A., Zoppini A. Relationship of soluble interleukin-2-receptor and interleukin-6 with class-specific rheumatoid factors during low-dose methotrexate treatment in rheumatoid arthritis. Rev Rhum Engl Ed. 1997 Feb;64(2):89–94. [PubMed] [Google Scholar]
  14. Straub R. H., Zeuner M., Antoniou E., Schölmerich J., Lang B. Dehydroepiandrosterone sulfate is positively correlated with soluble interleukin 2 receptor and soluble intercellular adhesion molecule in systemic lupus erythematosus. J Rheumatol. 1996 May;23(5):856–861. [PubMed] [Google Scholar]
  15. Suenaga Y., Yasuda M., Yamamoto M., Nonaka S., Wada T., Shiokawa S., Nobunaga M. Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis. Clin Rheumatol. 1998;17(4):311–317. doi: 10.1007/BF01451012. [DOI] [PubMed] [Google Scholar]
  16. Symmons D. P., Hassell A. B., Gunatillaka K. A., Jones P. J., Schollum J., Dawes P. T. Development and preliminary assessment of a simple measure of overall status in rheumatoid arthritis (OSRA) for routine clinical use. QJM. 1995 Jun;88(6):429–437. [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES